Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Zhejiang Taimei Medical Technology Co Ltd Class H ( (HK:2576) ).
Zhejiang Taimei Medical Technology Co., Ltd. announced an estimated reduction in net loss for the fiscal year 2024, with a projected net loss of not more than RMB220.0 million, down from RMB356.4 million in 2023. This improvement is attributed to increased gross profit margins and decreased selling and R&D expenses. Additionally, the adjusted net loss (non-IFRS measure) is expected to be not more than RMB60.0 million, a significant reduction from RMB317.1 million in 2023, highlighting the company’s focus on financial efficiency.
More about Zhejiang Taimei Medical Technology Co Ltd Class H
Zhejiang Taimei Medical Technology Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on developing core competitive products and improving management efficiency, which has led to a reduction in expenses.
YTD Price Performance: 0.93%
Average Trading Volume: 141,054
Technical Sentiment Consensus Rating: Strong Buy
For an in-depth examination of 2576 stock, go to TipRanks’ Stock Analysis page.